
|Videos|March 7, 2023
A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing
Dr Vail shares insight into his ideal institutional approach to biomarker testing for NSCLC, emphasizing the need for local molecular pathology expertise and available in-house biomarker panels.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
4
Why Awareness of Alcohol's Breast Cancer Risk Still Lags Decades Behind Tobacco
5




























